U.S. FDA on September 4, 2012 approved by the U.S. Wyeth (WYETH PHARMS INC) of Bosutinib (trade name: Bosulif) listed tablets for the treatment of chronic acceleration or blastic phase Philadelphia chromosome-positive (Ph +) and the treatment of the past resistance or intolerant chronic myeloid leukemia in adults (CML). The drug is a tyrosine kinase inhibitor, can promote the CML l-Bcr-Ab1 kinase inhibition
FDA approved leukemia drugs listed Bosutinib
ReplyDeleteU.S. FDA on September 4, 2012 approved by the U.S. Wyeth (WYETH PHARMS INC) of Bosutinib (trade name: Bosulif) listed tablets for the treatment of chronic acceleration or blastic phase Philadelphia chromosome-positive (Ph +) and the treatment of the past resistance or intolerant chronic myeloid leukemia in adults (CML). The drug is a tyrosine kinase inhibitor, can promote the CML l-Bcr-Ab1 kinase inhibition
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Ruxolitinib phosphate
INCB018424 sulfate
Baricitinib
AZD-1480
TG-101348
TG101209
CYT387
LY2784544
Baricitinib
WHI-P97